Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016
In the past decade non-alcoholic liver disease became the most frequently diagnosed liver disease in developed countries. At the same time, the dramatic rise in the incidence of hepatocellular carcinoma is attributed to this common metabolic disorder, and mainly to its severe form, non-alcoholic steatohepatitis. The risk factors of these associated diseases are genetic predisposition, obesity and diabetes as well as chronic low grade necro-infammation, which often leads to liver fibrosis. Free fatty acids, cytokines, lipotoxicity, insulin resistance, microRNS dysregulation and alteration in intestinal microbiota play a pivotal role in the pathogenesis. Treatment of non-alcoholic fatty liver disease - weight reduction and physical exercise in obesity, metformin in diabetes, statins in dyslipidemia and, as a new option, obeticholic acid - may diminish the risk of the hepatocellular carcinoma related to this metabolic disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:157 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 157(2016), 25 vom: 19. Juni, Seite 987-94 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Nem alkoholos zsírmáj és hepatocellularis carcinoma - 2016 |
|---|
| Beteiligte Personen: |
Pár, Alajos [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.09.2016 Date Revised 16.11.2017 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2016.30425 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM261284916 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM261284916 | ||
| 003 | DE-627 | ||
| 005 | 20231224195224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2016.30425 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0870.xml |
| 035 | |a (DE-627)NLM261284916 | ||
| 035 | |a (NLM)27287838 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Pár, Alajos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016 |
| 246 | 3 | 3 | |a Nem alkoholos zsírmáj és hepatocellularis carcinoma - 2016 |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2016 | ||
| 500 | |a Date Revised 16.11.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In the past decade non-alcoholic liver disease became the most frequently diagnosed liver disease in developed countries. At the same time, the dramatic rise in the incidence of hepatocellular carcinoma is attributed to this common metabolic disorder, and mainly to its severe form, non-alcoholic steatohepatitis. The risk factors of these associated diseases are genetic predisposition, obesity and diabetes as well as chronic low grade necro-infammation, which often leads to liver fibrosis. Free fatty acids, cytokines, lipotoxicity, insulin resistance, microRNS dysregulation and alteration in intestinal microbiota play a pivotal role in the pathogenesis. Treatment of non-alcoholic fatty liver disease - weight reduction and physical exercise in obesity, metformin in diabetes, statins in dyslipidemia and, as a new option, obeticholic acid - may diminish the risk of the hepatocellular carcinoma related to this metabolic disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a bél-baktériumflóra | |
| 650 | 4 | |a cancer prevention | |
| 650 | 4 | |a citokinek | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a daganatprevenció | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a diagnózis | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a genetika | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a hepatocellularis carcinoma | |
| 650 | 4 | |a insulin resistance | |
| 650 | 4 | |a intestinal microbiota | |
| 650 | 4 | |a inzulinrezisztencia | |
| 650 | 4 | |a microRNA | |
| 650 | 4 | |a mikro-RNS | |
| 650 | 4 | |a nem alkoholos steatohepatitis | |
| 650 | 4 | |a nem alkoholos zsírmáj | |
| 650 | 4 | |a non-alcoholic fatty liver disease | |
| 650 | 4 | |a non-alcoholic steatohepatitis | |
| 650 | 4 | |a obeticholic acid | |
| 650 | 4 | |a obetikólsav | |
| 650 | 4 | |a surveillance | |
| 650 | 4 | |a szűrés | |
| 650 | 4 | |a terápia | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Fatty Acids, Nonesterified |2 NLM | |
| 700 | 1 | |a Pár, Gabriella |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 157(2016), 25 vom: 19. Juni, Seite 987-94 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:157 |g year:2016 |g number:25 |g day:19 |g month:06 |g pages:987-94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2016.30425 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 157 |j 2016 |e 25 |b 19 |c 06 |h 987-94 | ||